- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cancers
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 469KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 146KB)
Bevacizumab – March 2024
Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Vegzelma®
Last updated
30 May 2025